Randomized controlled trial of the effect of zinc supplementation on the mental development of Bangladeshi infants.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Their goal was to assess the effect of zinc supplementation on the developmental levels and behavior of Bangladeshi infants.

Who Took Part

The study group was 212 infants.

PubMed indexes the participants as infants.

For the present study, developmental levels were assessed in a subsample of 212 infants at 7 and 13 mo of age with use of the Bayley Scales of Infant Development, and the infants' behavior during the tests was observed.

The children's social backgrounds, weights, and lengths were also recorded.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the infants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some infants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

This was a randomized, double-blind, controlled trial conducted in Dhaka, Bangladesh.

What Was Measured

PubMed files the paper under topics including Anthropometry, Bangladesh, Child Development, Cognition, Developmental Disabilities, Dietary Supplements and Infant Behavior.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 212 infants.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (The American journal of clinical nutrition), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.